Novo Nordisk has filed 14 new lawsuits against telehealth companies and medical spas for distributing unapproved compounded versions of semaglutide. The company alleges these entities are violating laws regarding the corporate practice of medicine and using illicit ingredients to create 'knockoff' versions of Wegovy and Ozempic. This expands the company's total litigation to 132 cases across 40 states aimed at removing unsafe alternatives from the market.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.